Re-evaluation of clinical data of patients carrying pathogenic STRs other than C9orf72 and ATXN2 revealed that 7% did not have ALS, underscoring the value of genetic screening in patients with neurodegenerative symptoms. This evidence concerns the gene ATXN2 and amyotrophic lateral sclerosis.